MASTERMIND-Pneumonia Study (Also Known as Pneumonia Direct Pilot)
NCT06181669
Bacterial Infections, Bacterial Infections and Mycoses
Detroit, Michigan, United States
View Trial DetailsNCT Number: NCT00484588
Detect the clinical causitive pathogen of Ventilator Associated Pneumonia (VAP) patients by the bronchoalveolar lavage (BAL) method.
Looking for future studies?
Notify MeAll sexes
Observational
Any patient admitted into the chosen ICU will be a potential patient for this study. One of the main purposes of this study is to discover the various types of bacteria that cause VAP, and their frequency of occurrence. In order to obtain accurate and applicable results, as many subjects should be tested as possible. Approximately 500 patients will be included in this study.
VAP is defined as any lower respiratory tract infection that developed after 2 day of MV.
The criteria for clinical suspicion of pneumonia are as follows:
Presence of a new or persistent lung opacity on chest radiographs, plus two of the following items:
Every patient suspected of having pneumonia will undergo fiberoptic bronchoscopy to obtain samples by means of a bronchoalveolar lavage (BAL). VAP will be diagnosed based on results of BAL where BAL cultures yielding > 104 cfu/ml.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion:
Exclustion:
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
A Multi-Center Observational Surveillance of VAP Causing Bacteria Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06181669
Bacterial Infections, Bacterial Infections and Mycoses
Detroit, Michigan, United States
View Trial DetailsNCT07255742
Cross Infection, Disease Attributes
Tanta, Egypt
View Trial DetailsNCT05671328
Aspergillosis, Bacterial Infections and Mycoses
Lille, France
View Trial DetailsNCT01948635
Critical Illness, Cross Infection
Lille, Nord, France
View Trial Details